Literature DB >> 21816687

Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.

Elizabeth A Guancial1, Mary-Ellen Taplin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21816687      PMCID： PMC3388748          DOI： 10.1016/j.clgc.2011.06.001

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  16 in total

Review 1.  Coagulopathy in prostate cancer.

Authors:  C de la Fouchardière; A Flechon; J P Droz
Journal:  Neth J Med       Date:  2003-11       Impact factor: 1.422

2.  Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole.

Authors:  M R Litt; W R Bell; H A Lepor
Journal:  JAMA       Date:  1987-09-11       Impact factor: 56.272

3.  Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer.

Authors:  Ignacio Duran; Ian F Tannock
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

4.  Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Authors:  Stéphane Oudard; Eugeniu Banu; Philippe Beuzeboc; Eric Voog; Louis Marie Dourthe; Anne Claire Hardy-Bessard; Claude Linassier; Florian Scotté; Adela Banu; Yvan Coscas; François Guinet; Marie-France Poupon; Jean-Marie Andrieu
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid.

Authors:  D L Cooper; A B Sandler; L D Wilson; T P Duffy
Journal:  Cancer       Date:  1992-08-01       Impact factor: 6.860

7.  Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.

Authors:  S Sallah; G A Gagnon
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

8.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer.

Authors:  F C Lowe; W J Somers
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.